APOE and Alzheimer disease: An antagonistic pleiotropy model has been proposed for the pathogenicity of APOE4 in inflammation-associated late-life diseases, including AD (Jasienska et al., 2015), arteriosclerosis (Mahley, 1988), multiple sclerosis (Chapman et al., 2001), ischemic cerebrovascular disease (McCarron et al., 1999), sleep apnea (Kadotani et al., 2001), and pathologies resulting from traumatic brain injury (Friedman et al., 1999).